Global Infectious Disease Partnerships Report 2022: Access to 2,900 agreements and contractual documents

company logo

Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) — The “Global Partnership Against Infectious Diseases 2015-2022: Agreement Trends, Players and Financials” report has been added to from offer.

The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available agreements and contractual documents for over 2,900 infectious disease agreements.

Most of the agreements included in the report occur when a licensee obtains a right or option to license the product or technology from a licensor. More often than not these days, these agreements tend to be multi-component, including both collaborative R&D and an element of commercializing the results.

The report presents readers with comprehensive Infectious Disease Agreement trends, key players, and major agreement values, helping to understand how, why, and under what conditions companies are currently entering into Infectious Disease Agreements.

The report presents financial agreement term values ​​for infectious disease agreements, where applicable, a listing by aggregate values, upfront payments, milestones and royalties allowing readers to analyze and compare the value of ongoing agreements.

In addition, a comprehensive appendix is ​​provided with each report of all partnership agreements signed and announced since 2015. The appendices are organized by AZ company, stage of development at signing, type of agreement (collaborative R&D, co-promotion, license, etc.) and type of technology. Each transaction title is linked via Weblink to an online version of the transaction record and, where applicable, the contract document, providing easy access to each contract document upon request.

The report also includes numerous tables and figures that illustrate trends and activity in infectious disease partnerships and deals since 2015.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of infectious disease technologies and products.

The early chapters of this report provide direction on deal trends in the infectious disease space.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of infectious disease transaction trends since 2015, covering trends by year, type of transaction, stage of development, type of technology and therapeutic indication.

Chapter 3 includes an analysis of the terms of the financial agreement covering aggregate value, upfront payment, milestone payments and royalty rates.

Chapter 4 reviews major infectious disease deals since 2015. Deals are listed by aggregate value. The chapter includes the top 25 most active infectious disease traders, along with a comprehensive list of the agreements to which they are party. When the agreement has an agreement contract published to the SEC, a link provides online access to the contract.

Chapter 5 provides full access to infectious disease agreements since 2015 when an agreement contract is available, providing the user with direct access to contracts filed with SEC regulators. Each transaction title is linked via Weblink to an online version of the transaction record contract document, providing easy access to each contract document upon request.

Chapter 6 provides a comprehensive directory of all infectious disease partnership offerings by specific infectious disease target announced since 2015. The chapter is organized by specific infectious disease therapeutic target. Each transaction title is linked via Weblink to an online version of the transaction record and, where applicable, the contract document, providing easy access to each contract document upon request.

Report scope

The Global Partnership on Infectious Diseases 2015-2022 includes:

  • Trends in infectious disease transactions in the biopharmaceutical industry since 2015

  • Access to master, initial, milestone and royalty data

  • Access to hundreds of infectious disease contract documents

  • Full access to over 2900 infectious disease transaction records

  • Top infectious disease deals by value since 2015

  • Most active infectious disease negotiators since 2015

The report includes offers for the following indications:

  • Bacteria: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Staphylococcus aureus resistant to methicillin (MRSA), Mycobacterium avium, pertussis (whooping cough), Pseudomonas aeruginosa, salmonella, sepsis, tetanus, tuberculosis (TB), as well as other bacterial indications

  • Viral: colds, cytomegalovirus, Ebola, FIV, foot and mouth disease, hepatitis A, B, C, D, herpes simplex, HIV, influenza, H5N1 (avian flu), H1N1 (swine flu), Japanese encephalitis, polio, respiratory syncytial virus ( RSV), Zika, as well as other viral indications.

  • Parasite

  • Fungal: nail psoriasis, onychomycosis (nail infection), as well as other fungal indications

  • Tropical: African trypanosomiasis (sleeping sickness), dengue fever, malaria, West Nile virus, yellow fever, as well as other tropical indications

In Global Infectious Diseases Partnering 2015 to 2022, available offers and contracts are listed by:

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • What is the duration of the agreement?

  • How are the main terms of the agreement defined?

  • How are IPRs managed and owned?

  • Who is responsible for marketing?

  • Who is responsible for development, supply and manufacturing?

  • How are confidentiality and publication managed?

  • How to settle disputes?

  • Under what conditions can the agreement be terminated?

  • What happens if the owner changes?

  • What sub-licensing and sub-contracting arrangements have been agreed upon?

  • What boilerplate clauses does the company insist on?

  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

  • What jurisdiction does the company insist on for contract law?

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in Infectious Disease Transactions
2.1. Introduction
2.2. Infectious diseases associate over the years
2.3. Infectious Disease Partnerships by Deal Type
2.4. Infectious Disease Partnerships by Industry Sector
2.5. Partnerships for infectious diseases by stage of development
2.6. Partnerships for infectious diseases by type of technology
2.7. Partnership Infectious Diseases by therapeutic indication

Chapter 3 – Terms of the Infectious Disease Partnership Financial Agreement
3.1. Introduction
3.2. Financial Terms Disclosed for Infectious Disease Partnership
3.3. Infectious Disease Partnership Core Values
3.4. Infectious Diseases Process Upfront Payments
3.5. Milestone payments for infectious disease agreement
3.6. Infectious Disease Royalty Rates

Chapter 4 – Main agreements and negotiators in the field of infectious diseases
4.1. Introduction
4.2. Most Active Partnership in Infectious Diseases
4.3. List of the most active negotiators in infectious diseases
4.4. Top infectious disease offerings by value

Chapter 5 – Directory of contractual documents in infectious diseases
5.1. Introduction
5.2. Partnership agreements for infectious diseases when the contractual document is available

Chapter 6 – Dealmaking Infectious Diseases by therapeutic target
6.1. Introduction
6.2. Offers by therapeutic target Infectious Diseases

Annex 1 – Directory of infectious disease transactions by AZ company since 2015
Appendix 2 – Directory of infectious disease transactions by type of transaction since 2015
Annex 3 – Directory of infectious disease transactions by stage of development since 2015
Annex 4 – Directory of infectious disease transactions by type of technology since 2015

For more information on this report, visit

CONTACT: CONTACT: Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

About Michael Bill

Check Also

Varadkar says there is no indication the tech giants will close Irish offices

Leo Varadkar said the government has asked IDA Ireland and Enterprise Ireland to step up …